Core Viewpoint - A class action lawsuit has been filed against Walgreens Boots Alliance, Inc. for failing to disclose significant regulatory compliance issues during the Class Period from April 2, 2020, to January 16, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit alleges that Walgreens engaged in widespread violations of federal law regarding prescription medication dispensation and reimbursement [5]. - It claims that Walgreens' public statements were materially false and misleading, leading to investor damages when the truth was revealed [5]. - The lawsuit indicates that Walgreens' revenues from prescription sales were unsustainable due to unlawful conduct [5]. Group 2: Participation Information - Investors who purchased Walgreens common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm directly [3][6]. - A lead plaintiff must be appointed by March 31, 2025, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 [4]. - The firm has been recognized for its leadership in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [4]. - Investors are encouraged to select qualified counsel with a proven success record, as many firms may lack comparable experience [4].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Integral Ad Science Holding Corp. common stock, alleging that the company failed to disclose significant competitive pricing pressures and misleading public statements during the Class Period from March 2, 2023, to February 27, 2024 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that during the Class Period, IAS faced increased competitive pricing pressures, leading to price cuts due to weakening demand and slowing revenue growth [5]. - It is alleged that IAS's pricing function was no longer favorable, and the company could not sustain its pricing or drive price increases [5]. - The lawsuit states that IAS's public statements were materially false and misleading, resulting in damages to investors when the true details became known [5]. Group 2: Class Action Participation - Investors who purchased IAS common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm directly for more information [3][6]. - A lead plaintiff is needed to represent other class members, and interested parties must move the Court by March 31, 2025 [1][3].

$215 Million in Residential Sales Volume in 2024 Secures Elite RankingMENLO PARK, Calif., Jan. 29, 2025 /PRNewswire/ -- Coldwell Banker Realty is pleased to announce that the McNair Group, led by luxury real estate professional Billy McNair, has been ranked as its 2024 No. 1 top-performing medium agent team and achieved the Society of Excellence designation, which is reserved for only the top 1 percent of Coldwell Banker agents in the nation. Medium teams are made up of three to six people, and the designat ...

Over 230 Italian and U.S. executives, Italian government leaders, and investors attended the eighth edition of "Italy On the Move" Seven life sciences executives provided business insights during "Navigating Transatlantic Partnerships in Life Sciences" panel discussion and five Italian startups pitched their unique breakthroughs and investment opportunities Director General for the Promotion of Italy Mauro Battocchi discussed private and public/institutional financial opportunities in the €270 Billion Ita ...

NEW YORK, Jan. 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Caribou Biosciences, Inc. (NASDAQ: CRBU) between July 14, 2023 and July 16, 2024, both dates inclusive (the “Class Period”), of the important February 24, 2025 lead plaintiff deadline. SO WHAT: If you purchased Caribou securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangem ...

NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Enphase Energy, Inc. (NASDAQ: ENPH) between April 25, 2023 and October 22, 2024, both dates inclusive (the “Class Period”), of the important February 11, 2025 lead plaintiff deadline. SO WHAT: If you purchased Enphase common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arran ...

TOP RANKED ROSEN LAW FIRM Encourages Paladin Energy Ltd Investors to Inquire About Securities Class Action Investigation - PALAF ...

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Sun Communities, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SUI ...

TOP RANKED ROSEN LAW FIRM Encourages Micron Technology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MU ...

NEW YORK, Jan. 16, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of BioAge Labs, Inc. (NASDAQ: BIOA) pursuant and/or traceable to BioAge’s initial public offering conducted on September 26, 2024 (the “IPO”), of the important March 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased BioAge stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: T ...